維亞生物(01873.HK)全年經調整利潤升134.7%至3.18億元 末期息1.5港仙
格隆匯3月31日丨維亞生物(01873.HK)公佈,截至2019年12月31日止年度,集團實現收益3.23億元人民幣(單位下同),同比增長53.9%;毛利1.56億元,同比增長47.8%;淨利潤2.66億元,同比增長193.5%;經調整淨利潤3.18億元,同比增長134.7%;基本每股盈利0.22港元,擬派末期股息每股0.015港元。
2019年全年,集團的CFS業務累計向客户交付超過1.37萬個蛋白結構和獨立藥物靶標超過1200個。於報告期內,集團亦持續擴展廣泛多元的優質客户羣,客户訂單增幅明顯。CFS業務收入由去年同期1.55億元大幅增加至2.46億元,較去年同期增幅58.8%。2019年全年,集團EFS業務的收入為7750萬元,較去年同期增長約40.0%。
報告期內,集團研發費用約為4500萬元,較2018年度約2530萬元增加77.9%。上述增加乃主要由於研發人員數量增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.